Time-of-Day Immunotherapy Administration and Outcomes in Advanced Cancers

Authors:

Top Cited Papers
Open Access
Abstract
Importance: Circadian rhythms regulate immunity, which may influence the effectiveness of immune checkpoint inhibitor (ICI). Whether the time of ICI administration is associated with clinical outcomes in advanced cancers remains unclear. Objective: To evaluate the association between time of day of ICI administration and oncologic outcomes in patients with advanced solid tumors. Data Sources: MEDLINE (via PubMed), Embase, and Web of Science Core Collection were searched in February 2026 to identify eligible studies. Study Selection: Randomized clinical trials and prospective or retrospective cohort studies were included that compared early vs late time-of-day ICI administration and reported overall survival (OS) and progression-free survival (PFS). Data Extraction and Synthesis: This systematic review and meta-analysis adhered to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses reporting guideline. Two authors independently extracted data and assessed risk of bias. Random-effects meta-analyses were performed using the inverse-variance method. Main Outcomes and Measures: The primary outcomes were OS and PFS. These outcomes were reported as hazard ratios (HRs) with 95% CIs for early vs late ICI administration. Results: Of the 7892 records screened, 28 studies with 5919 patients were included: 1 prospective cohort study (62 patients) and 27 retrospective cohort studies (5857 patients). Earlier ICI administration was associated with longer OS (HR, 0.61; 95% CI, 0.52-0.71) and PFS (HR, 0.65; 95% CI, 0.57-0.74). Cancer-type subgroup analyses showed associations with longer OS and PFS in non–small cell lung cancer (NSCLC) (OS: HR, 0.61 [95% CI, 0.49-0.78]; PFS: HR, 0.66 [95% CI, 0.53-0.81]), gastric cancer (OS: HR, 0.61 [95% CI, 0.49-0.77]; PFS: HR, 0.62 [95% CI, 0.43-0.89]), renal cell carcinoma (RCC) (OS: HR, 0.60 [95% CI, 0.40-0.90]; PFS: HR, 0.70 [95% CI, 0.50-0.98]), small cell lung cancer (OS: HR, 0.37 [95% CI, 0.27-0.53]; PFS: HR, 0.48 [95% CI, 0.36-0.65]), and biliary tract cancer (OS: HR, 0.62 [95% CI, 0.41-0.93]; PFS: HR, 0.55 [95% CI, 0.38-0.79]). Conclusions and Relevance: In this systematic review and meta-analysis of nonrandomized studies, early immunotherapy administration was associated with improved outcomes. Randomized clinical trials are needed to establish causality and inform clinical implementation.

This publication has 52 references indexed in Scilit: